Aurora Kinase
Aurora kinase inhibitors target the Aurora kinases, a family of serine/threonine kinases that play a critical role in the regulation of mitosis. These kinases are essential for proper chromosome alignment, segregation, and cytokinesis during cell division. Abnormal Aurora kinase activity can lead to uncontrolled cell proliferation and cancer. By inhibiting Aurora kinases, these compounds can induce cell cycle arrest and apoptosis in cancer cells, making them valuable tools in cancer research and therapy. At CymitQuimica, we offer a wide range of high-quality Aurora kinase inhibitors to support your research in cell cycle regulation, mitosis, and oncology.
Found 114 products of "Aurora Kinase"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Centrinone
CAS:Centrinone (LCR-263) (LCR-263) is a reversible inhibitor of polo-like kinase 4 (PLK4; Ki:0.16 nM).Formula:C26H25F2N7O6S2Purity:98.76%Color and Shape:SolidMolecular weight:633.65dAURK-4 hydrochloride
dAURK-4 hydrochloride, a derivative of Alisertib, functions as a potent and selective degrader of AURKA (Aurora A), exhibiting anticancer properties [1].Formula:C52H53Cl2FN8O12Purity:99.44%Color and Shape:SolidMolecular weight:1071.93NU6140
CAS:NU6140 is a selective inhibitor of CDK2-cyclin A (IC50, 0.41 μM).Formula:C23H30N6O2Purity:98.33%Color and Shape:SolidMolecular weight:422.52Ref: TM-T16359
2mg39.00€5mg60.00€10mg92.00€25mg177.00€50mg285.00€100mg414.00€200mg580.00€1mL*10mM (DMSO)67.00€Tinengotinib
CAS:Tinengotinib is a multikinase inhibitor that targets a series of kinases , including Aurora kinases A/B, JAK1/2, FGFR1/2/3, VEGFRs, and many other kinases.Formula:C20H19ClN6OPurity:99.05%Color and Shape:SolidMolecular weight:394.86TAK-901
CAS:TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among othersFormula:C28H32N4O3SPurity:99.02% - 99.59%Color and Shape:SolidMolecular weight:504.64Ref: TM-T2709
1mg35.00€5mg70.00€10mg104.00€25mg202.00€50mg329.00€100mg525.00€200mg748.00€1mL*10mM (DMSO)79.00€Aurora-A ligand 1
CAS:Aurora-A ligand 1 is a potent and selective inhibitor of Aurora-A, exhibiting a dissociation constant (Kd) of 0.85 nM. It serves as a target protein ligand [PROTAC target protein ligand] in the development of PROTAC Aurora-A degraders with antitumor activity. Additionally, Aurora-A ligand 1 is utilized in the synthesis of HLB-0532259, which exhibits antitumor effects against neuroblastoma.Formula:C21H23N5O3Color and Shape:SolidMolecular weight:393.439GSK-1070916
CAS:GSK-1070916 (GSK-1070916A) is a reversible and ATP-competitive inhibitor of Aurora B/C with IC50 of 3.5 nM/6.5 nM.Formula:C30H33N7OPurity:99.73%Color and Shape:SolidMolecular weight:507.63CD532 hydrochloride
CD532 hydrochloride, potent Aurora A inhibitor (IC50=45 nM), hampers MYCN protein, changes AURKA's shape, aids cancer research.Color and Shape:SoliddAurAB2
dAurAB2 is a bifunctional PROTAC capable of effectively degrading Aurora-A and Aurora-B, with DC50 values of 59 nM and 39 nM, respectively. It reduces N-Myc levels in MYCN-amplified IMR32 neuroblastoma cells and is valuable for neuroblastoma research.Color and Shape:Odour SolidPROTAC MPS1 degrader 1
PROTAC MPS1 degrader 1 (Compound 19) acts as a potent degrader of Monopolar spindle 1 (Mps1, TTK), AURKA, and AURKB, with DC50 values of 17.7, 108.7, and 570.3 nM respectively. It is utilized in the study of acute myeloid leukemia. (Pink: ligand for target protein; Black: linker; Blue: ligand for E3 ligase)Formula:C41H46N12O7Color and Shape:SolidMolecular weight:818.88SK2187
CAS:SK2187 is a selective degrader of AURKAPROTAC with a DC50 of approximately 10 nM. It exhibits growth-inhibitory effects on NGP cells, with an IC50 value of 101.5 nM. SK2187 is utilized in studies of MYCN-amplified neuroblastoma.Formula:C45H49ClFN7O11SColor and Shape:SolidMolecular weight:950.43Barasertib
CAS:AZD1152 is a pro-drug of Barasertib (AZD1152)-hQPA. Which is a highly selective Aurora B inhibitor with IC50 of 0.37 nM in a cell-free assay.Formula:C26H31FN7O6PPurity:99.92% - 99.97%Color and Shape:SolidMolecular weight:587.54CAM2602
CAM2602 is an inhibitor of Aurora A-TPX2 interaction, demonstrating a binding affinity of 19 nM with Aurora A. This compound has been shown to inhibit the growth of pancreatic cancer cells. In solid tumor xenograft models, CAM2602 increases the proportion of PH3-positive cells while decreasing the ratio of P-Thr288Aurora A-positive cells, ultimately inhibiting tumor growth.Color and Shape:Odour SolidHLB-0532259
CAS:HLB-0532259 is a PROTAC degrader that targets the degradation of Aurora-A and N-Myc. In non-MYCN amplified MCF-7 cells, it degrades Aurora-A with a DC50 of 20.2 nM, and in MYCN amplified SK-N-BE and Kelly cells, it degrades N-Myc with DC50 values of 179 nM and 229 nM, respectively. HLB-0532259 has demonstrated antitumor activity in mouse models. (Pink: ligand for target protein; Black: linker; Blue: ligand for E3 ligaseCereblon)Formula:C40H44N8O7Color and Shape:SolidMolecular weight:748.827Retreversine
CAS:Retreversine serves as an inactive control counterpart to Reversine, a pioneering class of ATP-competitive Aurora kinase inhibitor.Formula:C21H27N7OColor and Shape:SolidMolecular weight:393.49AURKA against 1
Compound Ac13, also termed AURKA against 1, acts as an inhibitor of the Aurora kinase (AURKA) with an IC50 of less than 0.5 nM, targeting the acetylation of endogenous lysine (K162) and exhibiting anti-tumor cell proliferation activity. The kinase activity of AURKA, acetylated at K162 and induced by AURKA against 1, is reversibly restored in HCT116 cells transfected with SIRT3.Formula:C28H32FN9O2Color and Shape:SolidMolecular weight:545.61TAS-119
CAS:TAS-119 (TAS-2104) is an orally available, selective and potent inhibitor of Aurora A with an IC50 of 1.0 nM.TAS-119 also inhibits Aurora B with an IC50 of 95Formula:C23H22Cl2FN5O3Purity:99.65%Color and Shape:SolidMolecular weight:506.36Ref: TM-T34787
1mg97.00€5mg235.00€10mg378.00€25mg748.00€50mg1,169.00€100mg1,644.00€1mL*10mM (DMSO)261.00€JB300
CAS:JB300 is a PROTAC-based compound that serves as a highly selective degrader of Aurora A, with a DC50 of 30 nM. It is utilized in cancer research. JB300 comprises the PROTAC target protein ligand MK-5108 [pink part], E3 ligase ligand Thalidomide-O-COOH [blue part], and PROTAC Linker Boc-NH-PEG2-C2-NH2 [black part]. The conjugate of the E3 ubiquitin ligase ligand and linker is Thalidomide-O-COOH-NH2-C2-PEG2-NH-Boc.Formula:C43H45ClFN7O10SColor and Shape:SolidMolecular weight:906.375SP-96
CAS:SP-96: Aurora B inhibitor, IC50=0.316 nM, selectively hinders MDA-MD-468 growth, GI50=107 nM, for triple-negative breast cancer research.
Formula:C25H20FN7OPurity:99.54%Color and Shape:SolidMolecular weight:453.47dAURK-4
CAS:dAURK-4, a derivative of Alisertib, functions as a potent and selective degrader of AURKA (Aurora A), exhibiting anticancer properties [1].Formula:C52H52ClFN8O12Color and Shape:SolidMolecular weight:1035.47
